Skip to main content
Sign In
 

Xiaoping Yang, Ph.D.

Assistant Professor, Division of Medical Oncology


 Xiaoping Photo

 

Postdoctoral Fellowship Training
Washington State University
Graduate Schools
PhD, Nankai University
Undergraduate Schools
BS, Hunan Normal University

                                                                                                         

Bio
Dr. Yang joined the University of Colorado School of Medicine, Division of Medical Oncology as a Research Associate in 2008 and then promoted to faculty as a Research Instructor in 2009 and an Assistant Professor in July 2011. He trained in drug design in Nankai University with Ph.D degree from 1994 to 1997 and worked as Associate Professor and Fully Professor of Organic Chemistry from 1998 to 2001 at Hunan University of Sciences and Technologies. He completed NIH-funded postdoctoral fellowship training in molecular biology at Washington State University from 2001 to 2003. Then, he worked as a research scientist in school of pharmacy at University of Wyoming from 2003 to 2006 and then came to Department of Surgery of University of Colorado Anschutz Medical Campus as a Research Instructor from 2006 to 2008.
 
Research
Dr. Yang is an associate member of the Developmental Therapeutics and a full member of Genitourinary (GU) Medical Oncology Program. These comprehensive programs include multidisciplinary cancer clinics, tumor boards, and research endeavors. Dr. Yang is interested in developing novel therapeutic treatments in GU cancers using both in vitro and in vivo working models. He was awarded the 2010 American Cancer Society IRG grant and is co-PI of several NIH and local grants.
 
Selected Publications
1.   Yang X* , La Rosa GF, Genova EE, Huber K,  Schaack J,  DeGregori J, Serkova NJ, Li Y, Su LJ, Kessler E, Flaig TW*. Oncogene. Simultaneous activation of Kras and inactivation of p53 in double transgenic Kras LSLG12D/+  . p53 fl/fl mice by Cre recombination induces urothelial hyperplasia but not carcinogenesis in bladder, in preparation (*correspondence author)
2.   Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glodé LM, Flaig TW. Diphtheria Toxin-Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer. Clin Cancer Res. 2013, 19(1):148-57
3.   Yang X, Bemis LT, Su LJ, Gao D, Flaig TW. Mir-125b regulation of androgen receptor signaling via modulation of the receptor complex co-repressor. Bio-Research, 2012, 1(2): 55-62 (highlighted by Science Time)
4.   Li Y*, Yang X*, Su LJ, Flaig TW. Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. Urology, 2011, 78, 233: e7-233, e13 (*equally contributed)
5.   Li Y, Yang X*, Su LJ, Flaig TW. VEGFR and EGFR Inhibition Increases Epithelial Cellular Characteristics and Chemotherapy Sensitivity in Mesenchymal Bladder Cancer Cells. Oncol. Rep., 2010,  24: 1019-1028 (*correspondence author)
6.   Yang X, Flaig TW. Novel Targeted Agents for the Treatment of Bladder Cancer: Translating Laboratory Advances into Clinical Application. Int. Braz. J Urol., 2010, 36(3): 273-282
7.   Yang X, Fullerton DA, Su X, Ao L, Cleveland Jr. JC, Meng X. Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. J Am Coll Cardiol  2009; 53(6): 491-500 (Impact factor 14.640)
 
Funding
 
Completed:
 
ACS IRG #57-001-50      Yang (PI)                                     01/01/10-12/31/11
American Cancer Society
Establishment of an Orthotopical Murine Bladder Cancer Model Using Cre Recombination
Role: PI
 
1 R21 CA152375-01       Flaig, Park (MPI)                          07/01/10-06/30/13
NIH/National Cancer Institute  
Targeted Nanoparticle Thermoablation for the Treatment of Bladder Cancer
Role: Co-PI
 
HB09-1001                     Flaig (PI)                                      07/01/10-06/30/12
CU TTO/State Bioscience Award
DT-EGF for the Treatment of Bladder Cancer
Role:  Co-Investigator
 
Ongoing:
 
1R43CA174011-01          Glode (PI)                                    09/26/12-08/31/13
National Institutes of Health/National Cancer Institute
DT-EGF Toxic Fusion Protein for Treatment of Bladder Cancer
Role: Co-Investigator
 
CaSC grants                    Burton, Flaig (MPI)                       07/01/13-06/30/14
CSU Cancer Supercluster             
Phase 1 Evaluation of DAB389EGF for Canine Transitional Cell Carcinoma of the Bladder
Role: Co-Investigator
 
University of Colorado Denver

© The Regents of the University of Colorado, a body corporate. All rights reserved.

All trademarks are registered property of the University. Used by permission only.